

Featured data at AANEM and MGFA 2025

Johnson&Johnson

American Association of Neuromuscular & Electrodiagnostic Medicine

October 29 - November 1, 2025

MGFA Scientific Session at AANEM

October 29, 2025

San Francisco, California

Johnson & Johnson sponsored IMAAVY™ (nipocalimab-aahu) studies

Poster Number	Title	Presentation time
CLINICAL AND MOLECULAR INSIGHTS		
EPIC		
MGFA Poster #17	Efficacy and safety of nipocalimab vs efgartigimod in a randomized, open-label, Phase 3b, interventional trial including within class switching from efgartigimod to nipocalimab (EPIC): study design	Wednesday, October 29 2:30–3:30 PM PST
AANEM Poster #170		Thursday, October 30 6:15–6:45 PM PST Friday, October 31 9:30–10:00 AM PST
Nipocalimab vs. Efgartigimod Binding		
MGFA Poster #86	Insights into nipocalimab-neonatal fragment crystallizable receptor structure, binding affinity, and inhibition of immunoglobulin G recycling: comparison with efgartigimod	Wednesday, October 29 2:30–3:30 PM PST
AANEM Poster #209		Thursday, October 30 6:15–6:45 PM PST Friday, October 31 9:30–10:00 AM PST
IgG Changes After Switching		
MGFA Poster #94	Predicting total immunoglobulin G change from baseline when switching from efgartigimod to nipocalimab	Wednesday, October 29 2:30–3:30 PM PST
EFFICACY AND SAFETY IN ADOLESCENTS		
Nipocalimab Dose Adolescents		
MGFA Poster #96	Population pharmacokinetics and pharmacodynamics modeling of nipocalimab in adolescents aged 12 to less than 18 years with generalized myasthenia gravis	Wednesday, October 29 2:30–3:30 PM PST
VIBRANCE Cohort		
MGFA Poster #114	Safety and efficacy results of nipocalimab in adolescents with generalized myasthenia gravis during active-treatment and long-term extension phases: VIBRANCE-MG Phase 2/3 study	**Podium oral presentation:* Wednesday, October 29 10:30–10:40 AM PST *Poster presentation:* Wednesday, October 29 2:30–3:30 PM PST
VIBRANCE LTE		
AANEM Poster #202	Safety and efficacy results of nipocalimab in adolescents with generalized myasthenia gravis during active-treatment and long-term extension phases: VIBRANCE-Myasthenia Gravis Phase 2/3 study	Thursday, October 30 6:15–6:45 PM PST Friday, October 31 2:45–3:15 PM PST
LONG-TERM EFFICACY AND SAFETY		
Ph3 OLE: Placebo to Nipocalimab Switch		
MGFA Poster #87	Efficacy of nipocalimab in open-label extension in patients transitioned from placebo: results from VIVACITY-MG3 trial	Wednesday, October 29 2:30–3:30 PM PST
AANEM Poster #9		Thursday, October 30 6:15–6:45 PM PST Friday, October 31 2:45–3:15 PM PST
Ph3 VIVACITY OLE		
MGFA Poster #116	Long-term safety and efficacy of nipocalimab in generalized myasthenia gravis: VIVACITY-MG3 open-label extension phase results	**Podium oral presentation:* Wednesday, October 29 10:10–10:20 AM PST *Poster presentation:* Wednesday, October 29 2:30–3:30 PM PST

Johnson & Johnson sponsored IMAAVY™ (nipocalimab-aahu) studies

Poster Number	Title	Presentation time
LONG-TERM EFFICACY AND SAFETY (CONT.)		
Ph3 OLE Sustained Nipocalimab Efficacy and Stability		
AANEM Poster #175	Analysis of long-term efficacy of nipocalimab in myasthenia gravis: open-label extension of the VIVACITY-MG3 trial	Thursday, October 30 6:15–6:45 PM PST Friday, October 31 2:45–3:15 PM PST
EFFICACY AND SAFETY		
Ph3 VIVACITY MG-ADL/QMG		
MGFA Poster #9	Composite response to nipocalimab based on both myasthenia gravis activity of daily living and quantitative myasthenia gravis scores in patients with generalized myasthenia gravis	Wednesday, October 29 2:30–3:30 PM PST
AANEM Poster #176		Thursday, October 30 6:15–6:45 PM PST Friday, October 31 9:30–10:00 AM PST
Ph3 VIVACITY Post-Hoc QMG Domains		
MGFA Poster #23	Assessing severity in generalized myasthenia gravis: a Phase 3 study of nipocalimab using quantitative myasthenia gravis items and domains	Wednesday, October 29 2:30–3:30 PM PST
AANEM Poster #203		Thursday, October 30 6:15–6:45 PM PST Friday, October 31 9:30–10:00 AM PST
Ph3 VIVACITY HCRU		
MGFA Poster #27	Hospital resource utilization associated with nipocalimab versus placebo: post-hoc analysis of the VIVACITY-MG3 trial in generalized myasthenia gravis	Wednesday, October 29 2:30–3:30 PM PST
Ph3 VIVACITY Safety Profile		
MGFA Poster #43	Safety profile of nipocalimab, a new neonatal fragment crystallizable receptor blocker in the Phase 3 VIVACITY-MG3 study	Wednesday, October 29 2:30–3:30 PM PST
AANEM Poster #210		Thursday, October 30 6:15–6:45 PM PST Friday, October 31 2:45–3:15 PM PST
Ph3 VIVACITY NeuroQOL		
MGFA Poster #64	Fatigue assessed by neuro-quality of life in Phase 3 VIVACITY-MG3 trial of nipocalimab versus placebo in generalized myasthenia gravis	Wednesday, October 29 2:30–3:30 PM PST
Ph3 VIVACITY Treatment Satisfaction Assessment		
MGFA Poster #65	Assessment of patient-reported outcomes from the Phase 3 VIVACITY-MG3 study of nipocalimab in generalized myasthenia gravis	Wednesday, October 29 2:30–3:30 PM PST
Ph3 VIVACITY Treatment Response Predictors		
AANEM Poster #178	Predictors of composite response in myasthenia gravis based on patient and clinician-reported assessments—in VIVACITY-MG3 Phase 3 trial	Thursday, October 30 6:15–6:45 PM PST Friday, October 31 9:30–10:00 AM PST
Ph3 VIVACITY Ocular Effects		
AANEM Poster #208	Efficacy of nipocalimab in adult patients with moderate to severe ocular manifestations of generalized myasthenia gravis in Phase 3 VIVACITY-MG3 study	Thursday, October 30 7:30–8:00 AM PST Friday, October 31 9:30–10:00 AM PST
Vaccine Response Analysis		
MGFA Poster #29	Post-hoc analysis of clinically relevant anti-vaccine and anti-virus antibodies in patients treated with nipocalimab in VIVACITY-MG3 study	Wednesday, October 29 2:30–3:30 PM PST

Johnson & Johnson sponsored IMAAVY™ (nipocalimab-aahu) studies

Poster Number	Title	Presentation time
EFFICACY AND SAFETY (CONT.)		
PBPK Model on the Placental Transfer of FcRn Inhibitors		
MGFA Poster #93	Development of a whole-body physiologically-based pharmacokinetic model for FcRn inhibitors in pregnancy incorporating placental transfer	Wednesday, October 29 2:30–3:30 PM PST
IgG Subclasses		
MGFA Poster #95	Nipocalimab effect on immunoglobulin G subclasses in patients with generalized myasthenia gravis	Wednesday, October 29 2:30–3:30 PM PST
REAL WORLD EVIDENCE & PATIENT EXPERIENCE		
Exacerbations/Crisis Komodo		
MGFA Poster #32	Factors associated with exacerbations or crises in generalized myasthenia gravis	Wednesday, October 29 2:30–3:30 PM PST
MG Social Listening		
MGFA Poster #31	An analysis of digital conversations to understand patient perceptions of the dosing and administration of neonatal Fc receptor inhibitors for treatment of myasthenia gravis	Wednesday, October 29 2:30–3:30 PM PST
MGFA Patient Registry		
MGFA Poster #18	Identifying risk factors for exacerbation and symptom worsening—a retrospective cohort study of patients with myasthenia gravis in the United States	Wednesday, October 29 2:30–3:30 PM PST
Measures that Matter		
MGFA Poster #16	Design of a digital solution to improve myasthenia gravis patient symptom tracking in routine clinical care	Wednesday, October 29 2:30–3:30 PM PST
Patient Engagement Research Council		
MGFA Poster #22	Patient and caregiver experiences of symptom instability and unpredictability from a myasthenia gravis patient engagement research council: a generative AI-assisted analysis	Wednesday, October 29 2:30–3:30 PM PST
AANEM Poster #159		Thursday, October 30 6:15–6:45 PM PST Friday, October 31 2:45–3:15 PM PST
MGFA Poster #20	Mapping out the patient journey of generalized myasthenia gravis: insights and challenges	Wednesday, October 29 2:30–3:30 PM PST
ADELPHI DSP Wave 2		
MGFA Poster #67	Treatment-related characteristics among younger women with generalized myasthenia gravis	Wednesday, October 29 2:30–3:30 PM PST
AANEM Poster #315	Factors associated with myasthenia gravis – activities of daily living score in a real-world, United States population prescribed standard of care therapy	Thursday, October 30 6:15–6:45 PM PST Friday, October 31 2:45–3:15 PM PST
Komodo MG and Pregnancy		
AANEM Poster #337	Impact of generalized myasthenia gravis on pregnancy outcomes: findings from a healthcare claims database	Thursday, October 30 6:15–6:45 PM PST Friday, October 31 2:45–3:15 PM PST

Johnson & Johnson sponsored IMAAVY™ (nipocalimab-aahu) studies

Poster Number	Title	Presentation time
	CIDP	
CIDP PRO		
AANEM Poster #275	Refining a conceptual model of patient experiences in chronic inflammatory demyelinating polyneuropathy: integrating new patient perspectives	Thursday, October 30 6:15–6:45 PM PST Friday, October 31 9:30–10:00 AM PST
CIDP Adjunction in ARISE		
AANEM Poster #177	Nipocalimab in chronic inflammatory demyelinating polyneuropathy: diagnostic adjudication of the first 110 patients of the Phase 2/3 ARISE study	Thursday, October 30 6:15–6:45 PM PST Friday, October 31 2:45–3:15 PM PST

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about IMAAVY™?

IMAAVY™ is a prescription medicine that may cause serious side effects, including:

- **Infections** are a common side effect of IMAAVY™ that can be serious. Receiving IMAAVY™ may increase your risk of infection. Tell your healthcare provider right away if you have any of the following infection symptoms:
  - fever
  - chills
  - shivering
  - cough
  - sore throat
  - fever blisters
  - burning when you urinate
- **Allergic (hypersensitivity) reactions** may happen during or up to a few weeks after your IMAAVY™ infusion. Get emergency medical help right away if you get any of these symptoms during or after your IMAAVY™ infusion:
  - swollen face, lips, mouth, tongue, or throat
  - difficulty swallowing or breathing
  - itchy rash (hives)
  - chest pain or tightness
- **Infusion-related reactions** are possible. Tell your healthcare provider right away if you get any of these symptoms during or a few days after your IMAAVY™ infusion:
  - headache
  - rash
  - nausea
  - fatigue
  - dizziness
  - chills
  - flu-like symptoms
  - redness of skin

Do not receive IMAAVY™ if you have a severe allergic reaction to nipocalimab-aahu or any of the ingredients in IMAAVY™. Reactions have included angioedema and anaphylaxis.

Before using IMAAVY™, tell your healthcare provider about all of your medical conditions, including if you:

- ever had an allergic reaction to IMAAVY™
- have or had any recent infections or symptoms of infection.
- have recently received or are scheduled to receive an immunization (vaccine). People who take IMAAVY™ should not receive live vaccines.
- are pregnant, plan to become pregnant, or are breastfeeding. It is not known whether IMAAVY™ will harm your baby.
  Pregnancy Safety Study. There is a pregnancy safety study for IMAAVY™ if IMAAVY™ is given during pregnancy or you become pregnant while receiving IMAAVY™. Your healthcare provider should report IMAAVY™ exposure by contacting Janssen at 1-800-526-7736 or www.IMAAVY.com.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of IMAAVY™?
IMAAVY™ may cause serious side effects. See "What is the most important information I should know about IMAAVY™?"

The most common side effects of IMAAVY™ include: respiratory tract infection, peripheral edema (swelling in your hands, ankles, or feet), and muscle spasms.

These are not all the possible side effects of IMAAVY™. Call your doctor for medical advice about side effects. **You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.**

Please see the full Prescribing Information and Medication Guide for IMAAVY™ and discuss any questions you have with your doctor.

Dosage Form and Strengths: IMAAVY™ is supplied as a 300 mg/1.62 mL and a 1,200 mg/6.5 mL (185 mg/mL) single-dose vial per carton for intravenous injection.

Johnson&Johnson